RxDoctor Payments Data

Naveen Kumar, MD

Internal Medicine · Melbourne, FLNPI 1295729200

Payments from drug & device makers

$1,897in general payments, 2019–2025

Across 51 payments — averaging $37.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$335
  • Novo Nordisk$319
  • Genentech USA, Inc.$245
  • Novartis$203
  • Boehringer Ingelheim$155
  • GSK$124
  • plus $515 from 14 others

What the payments were for

  • Food & beverage$1,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,897 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$123,529
Medicare patients
124
Services billed
2,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$128,471
JardianceEmpagliflozin64$53,953
EliquisApixaban65$47,836
TradjentaLinagliptin29$25,647
TrulicityDulaglutide13$21,897
XareltoRivaroxaban12$20,170
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$16,060
EntrestoSacubitril/Valsartan11$11,545
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen256$10,815
Atrovent HfaIpratropium Bromide14$8,957
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,422
Varenicline Tartrate16$7,003
Aripiprazole OdtAripiprazole11$6,738
Sucralfate13$6,212
FarxigaDapagliflozin Propanediol11$6,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$319$128,47193 claims
Boehringer IngelheimJardiance, Tradjenta$155$79,60093 claims
PfizerEliquis$17$47,83665 claims
Lilly USA, LLCTrulicity$335$21,89713 claims
Johnson & JohnsonXarelto$64$20,17012 claims
NovartisEntresto$203$11,54511 claims
GSKTrelegy Ellipta$124$7,42212 claims
AstraZenecaFarxiga$55$6,02411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →